Tizanidine Tablet
Product Images NDC 70518-3181

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 70518-3181). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Tizanidine 2 mg tablet packaging label showing quantity of 60 tablets. The label includes the proprietary name 'tizANidine', dosage strength, and remarks that the tablets are not interchangeable with capsules. It also provides manufacturer information (Sun Pharma, Cranbury, NJ) and repackager details (RemedyRepack Inc., Indiana, PA). The label features storage instructions and a QR code.*

FDA Label Image

Tizanidine-1 (Tizanidine 1)

Chemical structure of the active ingredient Tizanidine, showing a chlorine-substituted bicyclic ring connected to a thiazole and an imidazoline moiety, with an associated hydrochloride group.*

FDA Label Image

Tizanidine-2 (Tizanidine 2)

A line graph depicting plasma Tizanidine concentration (ng/mL) over time in hours after dosing. It compares the concentration profiles of 4 mg Tizanidine tablets and capsules taken with and without food, showing peak concentrations occurring between 1 and 2 hours post-dose and a decline towards zero by 24 hours.*

FDA Label Image

Tizanidine-3 (Tizanidine 3)

Line graph showing improvement in Ashworth Score over time (hours post-dose) for 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The graph depicts greater improvement with higher tizanidine dose compared to placebo, measured up to 6 hours post-dose.*

FDA Label Image

Tizanidine-4 (Tizanidine 4)

A line graph depicting improvement in Ashworth Score over three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). The graph compares two groups: tizanidine (mean dose 28.8 mg) showing greater improvement (lower scores) and placebo with less improvement (higher scores). Error bars indicate variability in both groups.*

FDA Label Image

Tizanidine 2mg 70518 3181 01

Label for Tizanidine 2 mg oral tablets, packaged with a quantity of 30 tablets. The label shows the brand and generic name, strength, dosage form, and quantity. It includes the NDC number 70518-3181-01 and indicates repackaging by RemedyRepack Inc. Manufacturer Sun Pharma, Cranbury, NJ, is noted, along with storage instructions and a warning that tablets are not interchangeable with capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.